The country's first hydrochloride epinastine eye drops, Mingyanshu, debuted on Ali Health.

On November 4th, the first domestically approved and listed eye drops containing levocabastine hydrochloride were launched on Ali Health. Mingyanshu, as the first product containing this ingredient to be launched in China, has been included in the priority review list by the National Medical Products Administration (NMPA) Drug Evaluation Center, equivalent to passing consistency evaluation. The market launch of this drug provides a safe and effective new treatment option for patients with allergic conjunctivitis.